Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, MS, Paul Elson, Ramon V. Tiu, MD, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Katarina Paulic, Josephine Chan, Sherry Pierce, RN, BS, Elias Jabbour, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, MD, PhD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1720.

https://doi.org/10.1182/blood.V118.21.1720.1720

Published: 2011

Journal Articles

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

Sudipto Mukherjee, Chandana Reddy, Jay Ciezki, Ramon V. Tiu, MD, Edward A. Copelan, MD, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Katarina Paulic, Jaroslaw P. Maciejewski, MD, PhD, Brian J. Bolwell, Eric A. Klein, MD, Mikkael A. Sekeres, MD, MS

Blood (2011) 118 (21): 120.

https://doi.org/10.1182/blood.V118.21.120.120

Published: 2011

Journal Articles

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Sanjay R. Mohan, MD, Alex Fu, Ramon V. Tiu, MD, Edward Copelan, MD, Yogen Saunthararajah, MD, Anjali Advani, MD, Ronald Sobecks, MD, Manual Afable, Ricki Englehaupt, Katarina Paulic, Marc Earl, Pharm., D., R.Ph., Matt Kalaycio, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 4033.

https://doi.org/10.1182/blood.V116.21.4033.4033

Published: 2010

Journal Articles

Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Mikkael A. Sekeres, MD, MS, Alan F. List, MD, David Cuthbertson, Ronald Paquette, MD, Deborah Latham, R.N., Manual Afable, R.N., Katarina Paulic, Thomas P. Loughran, Jr., MD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2008) 112 (11): 221.

https://doi.org/10.1182/blood.V112.11.221.221

Published: 2008

Journal Articles

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Matt Kalaycio, MD, Mary Laughlin, MD, PhD, Ronald Sobecks, MD, Anjali Advani, MD, Katarina Paulic, Josephine Chan, Alison Vellani, Azra Raza, MD

Blood (2007) 110 (11): 1457.

https://doi.org/10.1182/blood.V110.11.1457.1457

Published: 2007

NARROW

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

Email alerts

ASH Publications

American Society of Hematology

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only